Zhejiang Starry Pharmaceutical: Information on the 2023 Annual General Meeting of Shareholders
Sitaili's announcement on holding a briefing on the results and cash dividends for the first quarter of 2023 and 2024
Zhejiang Starry Pharmaceutical: Board Audit Committee Rules of Procedure (April 2024)
The company's shareholder return plan for the next three years (2024-2026)
Report on the performance of supervisory duties of accounting firms by the Audit Committee of the Board of Directors in 2023
Sitaili's 2023 Board Audit Committee Performance Report
Zhejiang Starry Pharmaceutical: Rules of Procedure for the Special Meeting of Independent Directors (April 2024)
Zhejiang Starry Pharmaceutical: Board Nomination Committee Rules of Procedure (April 2024)
Stelli's 2023 Internal Control Evaluation Report
Stelli's announcement on the use of idle funds for cash management
Sitaili's announcement on the 2024 annual remuneration of the company's directors, supervisors and senior management
Stari's announcement on amending the company's articles of association
Zhejiang Starry Pharmaceutical: Articles of Association (revised in April 2024)
Stelli's announcement on the launch of foreign exchange hedging business
Announcement of Sitaili on requesting the shareholders' meeting to authorize the board of directors to handle matters relating to issuing shares to specific targets through simple procedures
Sitaili's Notice on Convening the 2023 Annual General Meeting of Shareholders
Zhejiang Starry Pharmaceutical: Board Strategy Committee Rules of Procedure (April 2024)
Zhejiang Starry Pharmaceutical: Board Remuneration and Assessor Meeting Rules of Procedure (April 2024)
Sitaili Announces Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Legal Opinion of Sitaili's 2024 First Extraordinary General Meeting of Shareholders
No Data